Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

Creative Commons License

CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., Ayli M.

TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.2, ss.137-142, 2017 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjh.2016.0092
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.137-142
  • Anahtar Kelimeler: Chronic myeloid leukemia, Nilotinib, Fertility, Mouse, Gonads, IMATINIB MESYLATE, SUCCESSFUL PREGNANCIES, TYROSINE KINASE, SPERMATOGENESIS, INHIBITION, TRANSITION, THERAPY, DISEASE, MICE, KIT
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters.